Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rodent models and accompanying in vitro strategies for studying the etiology and therapy of Parkinson's disease.

Journal of Parkinson's disease·2026
Same author

The road towards faster development of novel pharmacotherapies for persons with Parkinson's disease.

Journal of Parkinson's disease·2026
Same author

Progression of Dysarthria, Drooling, and Swallowing Disorders in Parkinson's Disease: A 1-Year Prospective Cohort Study.

American journal of speech-language pathology·2026
Same author

Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

A Systematic Comparison of Alpha-Synuclein Seed Amplification Assays for Increasing Reproducibility.

Annals of clinical and translational neurology·2026
Same author

Neuroinflammatory profiles and cellular localization of TNF-α associated with chronic vanadium neurotoxicity.

Metabolic brain disease·2026

Related Experiment Video

Updated: Jun 25, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

41.9K

Chronic Vanadium Exposure Promotes Aggregation of Alpha-Synuclein, Tau and Amyloid Beta in Mouse Brain.

O R Folarin1, F E Olopade2, T T Gilbert3

  • 1Department of Biomedical Laboratory Science, College of Medicine, University of Ibadan, Ibadan, Nigeria.

Journal of Neurochemistry
|May 16, 2025
PubMed
Summary

Prolonged vanadium exposure in mice caused brain protein buildup linked to Alzheimer's and Parkinson's diseases. These toxic changes, including alpha-synuclein and amyloid-beta aggregation, were reduced after vanadium withdrawal.

Keywords:
agingneurodegenerationprotein aggregationproteinopathiesvanadium

More Related Videos

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

7.5K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

5.8K

Related Experiment Videos

Last Updated: Jun 25, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

41.9K
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

7.5K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

5.8K

Area of Science:

  • Neuroscience
  • Toxicology
  • Environmental Health

Background:

  • Toxic metals can cause neurodegenerative diseases by forming protein aggregates.
  • Vanadium exposure is linked to neurological issues, including cognitive decline and neurodegeneration.

Purpose of the Study:

  • To investigate if prolonged vanadium exposure is a risk factor for Alzheimer's and Parkinson's diseases.
  • To examine the effects of vanadium on key neurodegenerative proteins: alpha-synuclein (α-syn), amyloid-beta (Aβ), and tau.

Main Methods:

  • Mice were exposed to vanadium via intraperitoneal injections for 6, 12, or 18 months.
  • Brain tissue was analyzed using immunofluorescence for protein aggregation and cellular changes.
  • A withdrawal group was studied to assess reversibility of effects.

Main Results:

  • Vanadium exposure led to pathological aggregation of α-syn, Aβ, and tau proteins in specific brain regions.
  • Neuronal degeneration, gliosis, and activation of glial cells were observed.
  • Proteinopathy and cellular changes were reduced after vanadium withdrawal, but effects persisted.

Conclusions:

  • Prolonged vanadium exposure promotes the abnormal accumulation of neurodegeneration-associated proteins.
  • These proteinopathies are exacerbated by aging with extended vanadium exposure.
  • Vanadium exposure may be a risk factor for neurodegenerative diseases like Alzheimer's and Parkinson's.